Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). (Q47229875)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 December 2017

Language	Label	Description	Also known as
English	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).	scientific article published on 28 December 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

phase II clinical trial

0 references

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

recurrent neural network

1 reference

based on heuristic

inferred from title

7

object named as

Ginna G Laport

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Louis S. Constine

4

object named as

Louis S Constine

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

author name string

Eileen P Smith

1

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Hongli Li

2

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Jonathan W Friedberg

3

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Lisa M Rimsza

5

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

James R Cook

6

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Leslie L Popplewell

8

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Leona A Holmberg

9

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Sonali M Smith

10

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Michael LeBlanc

11

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Stephen J Forman

12

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Richard I Fisher

13

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Patrick J Stiff

14

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

publication date

28 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

full work available at URL

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965270

0 references

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of p

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5965270

26 August 2018

Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/29289757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group

1 reference

https://pubmed.ncbi.nlm.nih.gov/29289757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group

1 reference

https://pubmed.ncbi.nlm.nih.gov/29289757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/29289757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2017.12.798

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 January 2018

http://europepmc.org/abstract/MED/29289757

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47229875&oldid=2268542011"